A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE3RecruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

April 17, 2028

Study Completion Date

April 17, 2028

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

BGB-16673

BGB-16673 will be administered orally

DRUG

Pirtobrutinib

Pirtobrutinib will be administered orally

Trial Locations (1)

RECRUITING

Sunshine Coast University Hospital and Health Services, Sunshine Coast